Overview
Erleada is approved by the U.S. Food and Drug Administration (FDA) to treat metastatic castration-sensitive prostate cancer (mCSPC) and nonmetastatic castration-resistant prostate cancer (nmCSPC). When taking Erleada, a person should also receive a gonadotropin-releasing hormone (GnRH) analog or have undergone bilateral orchiectomy (surgical removal of both testes). Erleada is also known by its drug name, apalutamide.

Erleada is an androgen receptor inhibitor. It works by blocking the effects of androgens (sex hormones like testosterone), which helps to slow the growth and spread of prostate cancer cells.

How do I take it?
Prescribing information states that Erleada is taken orally once daily, with or without food. The tablets should be swallowed whole. Erleada should be taken exactly as prescribed by a healthcare provider.

Side effects
Common side effects of Erleada include fatigue, arthralgia (joint pain), rash, decreased appetite, falls, weight loss, hypertension (high blood pressure), hot flushes, diarrhea, and bone fractures.

Rare but serious side effects may include cerebrovascular events (such as stroke) and ischemic heart disease (reduced blood flow to the heart), seizures, severe skin reactions including Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS), interstitial lung disease (a group of lung conditions causing inflammation or scarring), and embryo-fetal toxicity (risk of harm to an unborn baby).

For more information about this treatment, visit:
Erleada (Apalutamide) Tablets — Janssen Products